Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.
Gastric Cancer
DRUG: Anlotinib|DRUG: Placebo
Overall Survival (OS), From randomization until death (up to 24 months)
Progress free survival (PFS), each 42 days up to PD or death(up to 24 months)|Objective Response Rate (ORR), each 42 days up to intolerance the toxicity or PD (up to 24 months)|Disease Control Rate (DCR), each 42 days up to intolerance the toxicity or PD (up to 24 months)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.